Federated Hermes
ZNTL icon

Federated Hermes’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Federated Hermes’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Buy
65,520
+30,946
+90% +$79.9K ﹤0.01% 1533
2025
Q4 		$46.7K Sell
34,574
-6,545
-16% -$9.53K ﹤0.01% 1648
2025
Q3 		$62.1K Buy
41,119
+1,383
+3% +$2.07K ﹤0.01% 1635
2025
Q2 		$46.1K Sell
39,736
-712,781
-95% -$940K ﹤0.01% 1643
2025
Q1 		$1.2M Buy
752,517
+258,535
+52% +$558K ﹤0.01% 1066
2024
Q4 		$1.5M Buy
493,982
+10,644
+2% +$34.9K ﹤0.01% 1004
2024
Q3 		$1.78M Buy
483,338
+857
+0.2% +$3.12K ﹤0.01% 956
2024
Q2 		$1.97M Sell
482,481
-1,516,219
-76% -$16.9M ﹤0.01% 927
2024
Q1 		$31.5M Sell
1,998,700
-161,865
-7% -$2.23M 0.07% 317
2023
Q4 		$32.7M Buy
2,160,565
+212,872
+11% +$3.11M 0.08% 279
2023
Q3 		$39.1M Sell
1,947,693
-70,541
-3% -$1.79M 0.1% 235
2023
Q2 		$56.9M Buy
2,018,234
+531,236
+36% +$12.7M 0.14% 183
2023
Q1 		$25.6M Buy
1,486,998
+275,398
+23% +$5.58M 0.06% 324
2022
Q4 		$24.4M Buy
1,211,600
+125,000
+12% +$2.69M 0.07% 338
2022
Q3 		$23.5M Buy
1,086,600
+1,461
+0.1% +$40K 0.07% 339
2022
Q2 		$30.5M Buy
1,085,139
+134,206
+14% +$3.55M 0.08% 294
2022
Q1 		$43.9M Sell
950,933
-23,727
-2% -$1.28M 0.1% 257
2021
Q4 		$81.9M Sell
974,660
-307,723
-24% -$23.8M 0.15% 188
2021
Q3 		$85.5M Buy
1,282,383
+7,717
+0.6% +$445K 0.16% 176
2021
Q2 		$67.8M Sell
1,274,666
-129,673
-9% -$6.95M 0.13% 213
2021
Q1 		$60.9M Buy
1,404,339
+625,264
+80% +$26.9M 0.12% 227
2020
Q4 		$40.5M Hold
779,075
– – 0.08% 298
2020
Q3 		$25.5M Buy
+779,075
New +$27.3M 0.06% 364

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Federated Hermes's ZNTL Position: Q1 2026 in Review

Federated Hermes increased its Zentalis Pharmaceuticals (ZNTL) stake by 90% in Q1 2026, buying an estimated $79.9K and bringing the position to 65,520 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1533.

Federated Hermes first reported a position in ZNTL in Q3 2020 and has held it in 23 quarters since. The position peaked at $85.5M in Q3 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Federated Hermes held 65,520 shares of Zentalis Pharmaceuticals worth $153K as of Q1 2026.
  • Federated Hermes bought 30,946 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $79.9K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1533 holding.
  • Federated Hermes first reported a position in Zentalis Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • Federated Hermes's Zentalis Pharmaceuticals position peaked at $85.5M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.